<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5186">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821999</url>
  </required_header>
  <id_info>
    <org_study_id>Laser SARS-CoV2</org_study_id>
    <nct_id>NCT04821999</nct_id>
  </id_info>
  <brief_title>Diode Laser 940 nm in Management of Loss of Taste Sensation</brief_title>
  <official_title>Diode Laser 940 nm in Management of Loss of Taste Sensation in Patients With Post SARS-CoV 2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fayoum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fayoum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global pandemic has recently emerged by transmission of SARS-CoV2 virus. The virus has&#xD;
      had a massive impact on health, wealth and social aspects worldwide. Since the identification&#xD;
      of this virus in Wuhan, China, millions of cases has been diagnosed worldwide with mortality&#xD;
      rates ranging from 3% to 12 %&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      'Long COVID' is emerging as a phenomenon where patients have long-term unresolved symptoms&#xD;
      (8,9). These could be prolonged symptoms of SARS-CoV2 or a posteSARS-CoV2 syndrome for which&#xD;
      dysfunction of smell and taste sensation has been proposed.&#xD;
&#xD;
      The proposal presents the diode laser 940 as possible treatment for the loss of taste&#xD;
      sensation in patients with long SARS-CoV2. The effect of low levels of laser energy was first&#xD;
      discovered by Dr Endre Mester in 1967.5 Since then it has been used for various applications&#xD;
      in the field of medicine and dentistry and is broadly termed 'low level laser therapy'(LLLT)&#xD;
      or 'biostimulation' or 'phototherapy'. It is defined as a 'non-thermal' laser light&#xD;
      application using photons (light energy) from the visible and infrared spectrum for tissue&#xD;
      healing and pain reduction (North American Association of Laser Therapy-NAALT). Several in&#xD;
      vitro studies have demonstrated that the effects of laser light on wound healing are much&#xD;
      greater than obtained with light from other sources, such as light-emitting diodes&#xD;
      (LEDs).(10-13)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with SARS-CoV2 infection confirmed with PCR with loss of taste sensation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>taste sensation survey</measure>
    <time_frame>6 weeks</time_frame>
    <description>The participated patients will be assessed using the taste questionnaire using a category scale for rating taste intensity and a forced choice for identifying the taste quality of each sample ( salty, sweet and bitter).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>a 940-nm diode laser</intervention_name>
    <description>a 940-nm diode laser (EPIC™, BIOLASE, www.biolase.com) with an adjustable pain therapy handpiece capable of creating diffuse laser energy patterns ranging from 15 mm to 30 mm in size.</description>
    <arm_group_label>group I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A diagnosis of SARS-CoV2 with PCR. Age range from 18-60 years old Loss of taste sensation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnancy or contraceptive pills Lactation Any auto-immune disease that could affect the&#xD;
        oral mucosa On any neoplastic therapy. Uncontrolled diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alshaimaa Mohamed, PhD</last_name>
    <phone>+201006047940</phone>
    <email>aas16@fayoum.edu.eg</email>
  </overall_contact>
  <reference>
    <citation>Halboub E, Al-Maweri SA, Alanazi RH, Qaid NM, Abdulrab S. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res. 2020 Oct 30;34:e124. doi: 10.1590/1807-3107bor-2020.vol34.0124. eCollection 2020. Review.</citation>
    <PMID>33146320</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fayoum University</investigator_affiliation>
    <investigator_full_name>Alshaimaa Ahmed shabaan</investigator_full_name>
    <investigator_title>associate professor in oral &amp; maxillofacial Surgery Department</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV</keyword>
  <keyword>, loss of taste</keyword>
  <keyword>, Diode laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Ageusia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

